Sibutramine associated cardiac arrest in a Chinese healthy young lady
Introduction
Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an anti-obesity agent to increase metabolic rate and thermogenesis, redu ce app etite and promote weight loss. Its recommended daily dose is 10-20 mg. 1 It was removed from the market in US, Canada, Europe and Australia in 2010 after a post marketing study concerning its cardiovascular safety. 2, 3 The Department of Health in Hong Kong also removed it from the market since No v e m b e r 2 0 1 0 a f t e r t h e Fo o d a n d D r u g Administration (FDA) announcement. 4 A case of sudden cardiac arrest in a young lady who was prescribed with sibutramine for weight reduction is reported.
Case report
A 33-year-old lady presented to a local emergency department (ED) for sudden onset of shortness of breath and collapse at home in November 2010. During transport by the ambulance, she was comatose and had desaturation requiring oxygen therapy. Her blood pressure was 144/89 mmHg and pulse rate was 88/min. On arrival to the ED, she developed cardiac arrest at the triage station and was immediately resuscitated in the resuscitation room. The initial cardiac rhythm was asystole. She was intubated and has restoration of spontaneous circulation (ROSC) after 3 minutes of cardiopulmonary resuscitation. The arterial blood gas result after ROSC showed severe acidosis with pH 6.74 (7.35 to 7.45), pCO 2 23.4 (4.7 to 6.0 kPa) and base excess -16.6 (-3.0 to 3.0 mmol/L). The spot bedside blood glucose level was 10.4 mmol/L and the blood potassium level was 5.4 mmol/L. The electrocardiogram (ECG) revealed multifocal atrial tachycardia with ventricular ectopic in triplet and diffuse ST depression (Figure 1 ). The chest X-ray showed clear lung fields and normal heart size. She was transferred to the intensive care unit (ICU) for further management. The subsequent blood tests including complete blood picture, liver and renal function tests were normal. The serum Troponin I level was 0.055 which was within the normal range (reference range: <0.06 ng/ml). Computerised tomography of the brain was also normal. Her haemodynamic state was unstable requiring low dose inotropic support. Her conscious state improved and she was extubated on the next day after admission. The metabolic acidosis also gradually normalised. Repeat On further enquiry from the patient's relatives, the patient enjoyed good past health with no past history or family history of any cardiac disorder. She had been taking weight reduction agents for 11 days prior this admission, namely sibutramine 10 mg twice daily, propranolol and Qualicana (tiratricol). Echocardiogram on day 2 revealed dilated left ventricle (LV) with impaired LV systolic function (ejection fraction 42%) and hypokinetic basal segments. She was subsequently transferred to the cardiac care unit (CCU). Her haemodynamic state improved and the inotropic suppor t was eventually weaned off. Echocardiogram was repeated on day 5 and revealed improved LV systolic function with ejection fraction of 58%, normal chamber size and mildly hypokinetic basal septal region. Cardiac catheterisation revealed normal coronary artery. However, her thyroid function test result returned later and was found to have decreased sTSH level (0.13 mIU/L with reference range of 0.27-4.20 mIU/L). The free T3 and T4 were normal. Urine drug screening using liquid chromatography mas s sp ectrometr y id entified the pres ence of sibutramine and its metabolites (N-desmethylsibutramine and N-bisdesmethyl-sibutramine). Sibutramine, propranolol and tri-iodothyroacetic acid (T3 analogue or tiratricol) were found in the prescribed capsule. The patient was eventually discharged without neurological sequelae after a total of 13-day hospitalisation. She sought medical advice for other non-specific complaints at ED 11 days later and her ECG at that attendance was unremarkable with QTc interval 432 msec (Figure 2b) . She was follow-up 5 weeks after discharged and fully recovered clinically.
A follow-up echocardiogram was arranged 3 months after discharged and it revealed normal chambers size, satisfactory myocardial function with no regional wall motion abnormality, LVEF 66.3% and trivial tricuspid regurgitation. 
Discussion
This case report highlights a probable association between using sibutramine resulted in QT interval prolongation and cardiac arrest.
Sibutramine had been a widely used anti-obesity agent after approved by the FDA and introduced in the United States in 1997. It is rapidly absorbed after oral administration with elimination half-life of 1 hour. 5 It is metabolised by the cytochrome P450 (3A4) system in liver to form active metabolites. The peak plasma concentrations of the active metabolites, N-desmethylsibutramine and N-bisdesmethyl-sibutramine, are reached within 3-4 hours while the elimination halflife of them are about 14-16 hours. 6, 7 Sibutramine is usually well-tolerated and the common adverse effects are hyper tension, tachycardia, constipation, dry mouth, deranged liver function, irritability, dizziness, anxiety, insomnia, and headache. 8 A recent study showed patients with preexisting cardiovascular conditions receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke. 3 Moreover, there had been cases reports of young patients developed acute myocardial infarction, which was associated with coronar y vasospasm on normal coronary arteries. [9] [10] [11] As sibutramine inhibits noradrenaline, dopamine and serotonin reuptake, it shares similar actions with other QT interval-prolonging drugs. The blockade of potassium channel by sibutramine in animal has been proposed as a potential mechanism for prolonging the QT interval and triggering arrhythmia. Therefore, an a ss o cia tio n o f s ib u tr a min e wit h QT in ter va l prolongation is anticipated. There had been reported cases of patients developing cardiac arrest and QT interval prolongation with sibutramine treatment. Harrison-Woolrych et al reported a 40-year-old Caucasian woman taking sibutramine 15 mg daily for 25 days developing cardiac arrest with QTc 0.6 ms. 12 Ernest et al described a 51-year-old woman who sustained cardiac arrest with QTc 545 msec after starting sibutramine 15 mg daily for 10 weeks. The QT intervals of both patients were shortened after discontinuation of sibutramine. 13 Three cases of QT interval prolongation associated with sibutramine and 1 fatal case of torsade de pointes with cisapride coingestion were repor ted in the World Health Organization's international spontaneous reporting database (post-marketing surveillance). 12 Sibutramine was removed from the market worldwide including US, Canada, Europe and Australia since 2010 after a post marketing study of its cardiovascular safety.
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The Sibutramine Cardiovascular outcomes (SCOUT) study showed a higher rate of cardiovascular events including heart attack and stroke in obese and overweight patients using sibutramine than in patients managing their weight through exercise and diet alone. 1, 3 It was removed from the market in Hong Kong since November 2010 after the FDA announcement. 4 However, it may still be imported from sources like the internet or as adulterants. Physicians should aware of the possible availability of this agent.
Our patient had evidence of QT interval prolongation on her initial ECG but resolved after discontinuation of sibutramine. The attributable cause of sudden cardiac arrest could be tachyarrhythmias related to the QT interval prolongation. Toxicology screening tests showed absence of cocaine, amphetamine and other medications causing QT interval prolongation. The Naranjo score for the adverse drug reactions in our patient was 6 which showed a "probable" association between use of sibut ra min e a nd QT int er val prolongation on the basis of (1) previous conclusive reports of QT interval prolongation associated with sibutramine; (2) the appearance of this effect after administration of the drug; (3) the absence of alternative factors that could have caused the reaction on their own; and (4) the adverse reaction improved when the sibutramine was discontinued. 15 Tiratricol was also found in the capsule of the medication. It is a thyroid hormone analogue and is used in conditions with thyroid hormone resistance. It has also been reported to be used as adulterated products in slimming medications. 6 The abnormal thyroid function result in our patient was probably related to the exposure of tiratricol. "Off-label" use of tiratricol could result in severe complications including hyperthyroidism, heart failure and hypokalemic paralysis. Propranolol is a beta-blocker causing bradycardia and was prescribed to our patient with the intention to mask the undesirable effects of tiratricol and sibutramine. Tiratricol, propranolol and thyroid status are not associated with QT prolongation.
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Conclusion
Sibutramine can prolong QT interval resulting in life threatening arrhythmias. Despite the fact that it is banned, physicians should maintain vigilance on it as a responsible agent in slimming product intoxication.
